---
schema_version: "secwatch.filing_event.v1"
accession: "0001609550-23-000061"
form_type: "8-K"
ticker: "INSP"
cik: "0001609550"
company_name: "Inspire Medical Systems, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:30:28.057753+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Inspire Medical Q3 revenue $153.3M (+40% YoY); raises FY2023 guidance to $608-612M

## Summary
- Net loss narrowed to $8.5M ($0.29 per share) from $16.8M ($0.60) YoY.
- U.S. revenue $147.5M (+39%); OUS revenue $5.8M (+99%). Gross margin improved to 84.1%.
- Added 62 new U.S. implant centers (total 1,107) and 13 new sales territories (total 274).
- Surpassed 50,000 patients treated with Inspire therapy globally.
- FY2023 revenue guidance raised to $608-612M (49-50% growth); gross margin guidance maintained at 83-85%.

## SEC filing metadata
- accession: 0001609550-23-000061
- form_type: 8-K
- ticker: INSP
- cik: 0001609550
- company_name: Inspire Medical Systems, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/0001609550-23-000061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/insp-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001609550-23-000061
- JSON: https://secwatch.observer/filing/0001609550-23-000061.json
- Plain text: https://secwatch.observer/filing/0001609550-23-000061.txt

## Key facts
- Earnings Releases
  Inspire Medical Systems, Inc. reported full year 2023 results: revenue $608 million to $612 million. Guidance raised.
  - Period: full year 2023
  - Revenue: $608 million to $612 million
  - Guidance: raised
  - Result: guidance update
  source text: Inspire is increasing and narrowing its full year 2023 revenue guidance to between $608 million to $612 million, which represents growth of 49% to 50% over full year 2022 revenue of $407.9 million. This compares to the prior revenue guidance of $600 million to $610 million.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1609550/000160955023000061/0001609550-23-000061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.